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Abstract 
The relationship between long-term cholinergic dysfunction and risk of developing 
dementia is poorly understood. Here we used mice with deletion of the vesicular 
acetylcholine transporter (VAChT) in the forebrain to model cholinergic abnormalities 
observed in dementia. Whole genome RNA-sequencing of hippocampal samples 
revealed that cholinergic failure causes changes in RNA metabolism. Remarkably, key 
transcripts related to Alzheimer’s disease are affected. BACE1 for instance, shows 
abnormal splicing caused by decreased expression of the splicing regulator 
hnRNPA2/B1. Resulting BACE1 overexpression leads to increased APP processing 
and accumulation of soluble Aβ1-42. This is accompanied by age-related increases in 
GSK3 activation, tau hyper-phosphorylation, caspase-3 activation, decreased synaptic 
markers, increased neuronal death and deteriorating cognition. Pharmacological 
inhibition of GSK3 hyperactivation reversed deficits in synaptic markers and tau 
hyperphosphorylation induced by cholinergic dysfunction, indicating a key role for GSK3 
in some of these pathological changes. Interestingly, in human brains there was a high 
correlation between decreased levels of VAChT and hnRNPA2/B1 levels with increased 
tau hyperphosphorylation. These results suggest that changes in RNA processing 
caused by cholinergic loss can facilitate Alzheimer’s-like pathology in mice, providing a 
mechanism by which decreased cholinergic tone may increase risk of dementia.  
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Introduction 
Alzheimer’s disease (AD), the predominant form of dementia, is pathologically 
characterized by accumulation of amyloid plaques and neurofibrillary tangles that 
ultimately lead to neuronal death. One of the early alterations identified in AD-affected 
individuals with cognitive decline is a profound decrease in basal forebrain cholinergic 
neurons (Whitehouse et al., 1982), which gave rise to the cholinergic hypothesis of AD 
(Bartus et al., 1982). Accordingly, Alzheimer’s Disease Neuroimaging Initiative data 
reveal atrophy of the basal forebrain in individuals with mild cognitive impairment 
(Grothe et al., 2014), and increased forebrain cholinergic atrophy in Alzheimer’s-
affected individuals (Grothe et al., 2013). Cholinergic dysfunction correlates with 
decreased hippocampal volume and pathology (Teipel et al., 2014). Furthermore, recent 
epidemiological data suggest that long-term use of drugs with anti-cholinergic activity by 
elderly individuals increases the future risk of dementia (Gray et al., 2015). These 
observations reveal an intimate, but poorly understood relationship, between cholinergic 
dysfunction and the pathological and cognitive deficits in AD. However, whether 
cholinergic malfunction has a causal role in increasing the risk of dementia or regulating 
pathology is unknown. Moreover, the causal and temporal relationships between 
cholinergic malfunctioning and long-term changes in hippocampal neurons in AD are 
still unclear.  
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To test the capacity of cholinergic tone to regulate long-term functions in target 
cells we examined the hippocampal transcriptome in genetically-modified mice with 
compromised hippocampal cholinergic tone. Using forebrain-specific deletion of the 
vesicular acetylcholine transporter (VAChT), a protein required for acetylcholine (ACh) 
release (de Castro et al., 2009; Prado et al., 2013), we unveil that long-term cholinergic 
deficiency causes global changes in gene expression and alternative splicing in the 
hippocampus. This leads to abnormal alternative splicing of BACE1 with consequent 
age-dependent changes in amyloid precursor protein (APP) processing, tau hyper-
phosphorylation, hippocampal neuronal loss and cognitive decline. Comparative 
analyses in the AD brain enabled us to identify links between cholinergic deficiency and 
AD pathology, together supporting the notion that early cholinergic dysfunction may be 
a pivotal step in AD pathology initiation and progression. Our data provide potential 
mechanisms to explain how cholinergic deficiency may facilitate pathology in AD. 
Materials and Methods 
Mouse lines 
Generation of VAChTflox/flox mice was previously described (de Castro et al., 
2009). VAChTNkx2.1-Cre-flox/flox mice were generated by crossing VAChTflox/flox (crossed for 
5 generations with C57BL/6J) with the Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1- 
cre)2Sand/J), purchased from The Jackson Laboratory (JAX stock no. 008661). Unless 
otherwise stated, all control mice used were VAChTflox/flox littermates. All procedures 
were conducted in accordance with guidelines of the Canadian Council of Animal Care 
(CCAC) and in accordance with ARRIVE guidelines, at the University of Western 
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Ontario with an approved institutional animal protocol (2008-127). Only male mice were 
used for all experiments.  
RNA Sequencing 
Mouse hippocampal tissue was rapidly dissected and total RNA was extracted 
from individual samples using the PureLink RNA Mini Kit (Ambion). 2 µg of total RNA 
were then sent to the Centre for Applied Genomics, The Hospital for Sick Children, 
where the cDNA library was prepared using the TruSeq Stranded Total Sample 
Preparation kit (Illumina) and run in a HiSeq 2500 platform with coverage of 200-250 
million pair reads per lane. 5 animals were run per lane to obtain enough coverage for 
alternative splicing analysis (50 million pair reads per sample). The sequenced reads 
were aligned to the mouse genome using the TopHat program against the mouse 
genome in Ensembl (version EnsMart72) to enable quantification of splice junctions in 
addition to gene level measurements. Differential gene expression analysis was 
conducted using the Bioconductor DESeq package which accounts for the counts 
binomial distribution (Anders and Huber, 2010). Datasets are available on ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-3897. 
For human brains, we used the SQUARETM RNA library construction approach 
which utilizes different sets of 5’- and 3’-site specific primers to segregate all full-length 
transcripts into sub-pools defined by the selective nucleotides in the respective primers. 
Unlike traditional sequencing, which is based on the use of universal primers that 
produce a pool of fragmented RNA products for a given gene, we used 12 different sets 
of 3’-primers that complement all distinct di-nucleotides at transcript 3’-polyadenylation 
sites and enable separate sequencing of the corresponding intact RNA molecules for 
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each of the primer sets through barcoding. This unprecedented depth of segregated 
brain RNA-Seq data was made publicly accessible by establishing a user-friendly 
website where the sequenced variants for any given brain-expressed transcript can be 
found (http://apainad.weebly.com/). Sequencing files were processed and analyzed for 
differential expression and functional enrichment.  
 RNA sequencing libraries made from the temporal gyrus samples yielded an 
average of 6.0*106 (STD=2.0*106) uniquely aligned 75 base pair (bp) single end reads, 
or approximately 7.0*107 (STD=1.8*107) total read counts when combining all 12 
SQUARE fields for each sample. These reads were mapped against the 
GRGCh37/hg19 version of the Homo sapiens genome (http://genome.ucsc.edu/). 
Transcripts with more than 1 read per kilobase per million (RPKM) per SQUARE field 
were defined as being detected (Hebenstreit and Teichmann, 2011). An average of 
6610±1367 genes per field were detected across the 12 fields (details in Supplementary 
Table III). Expression criteria were set to RPKM>1 in at least one of the SQUARE fields, 
in at least 80% of the tested donor cohorts. 
Immunofluorescence  
Immunofluorescence experiments were performed as previously described (de 
Castro et al. 2009). Primary antibodies used were anti-Choline Transporter (CHT1; 
1:200), which was kindly donated by Dr. R. Jane Rylett, University of Western Ontario, 
London, Ontario, anti-hnRNPA2/B1 (1:200 Santa Cruz Biotechnology Catalog no. sc-
10035), anti-Cleaved caspase-3 (1:500 Thermo Fisher Scientific, Catalog no. PA5-
16335), anti-AT180 (1:1000 Thermo Fisher Scientific, Catalog no. EN-MN1040), anti-
NeuN (1:200 PhoshphoSolutions, Catalog no. 583-FOX3), anti-GFAP, anti-PSD95. 
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Sections were visualized by Zeiss LSM 510 Meta (Carl Zeiss, Oberkochen, Germany) 
confocal system (40x, 63x objectives, with an N.A. of 1.3 and 1.4, respectively) and by 
Leica TCS SP8 (Leica Microsystems Inc, Ontario, Canada) confocal system (63x 
objective, with an N.A. of 1.4), a 488-nm Ar laser and 633-nm HeNe laser were used for 
excitation of fluorophores. 
 Western Blotting 
Mouse hippocampi were collected, protein was isolated, and immunoblotting was 
performed as previously described using RIPA lysis buffer supplemented with protease 
and phosphatase inhibitors (Guzman et al., 2011). Band intensities were quantified 
using FluoroChemQ software (Thermo Fisher Scientific). 
Gene Ontology Analysis 
Gene ontology functional analysis was performed using the GOrilla software 
through the web application. Using the two-un-ranked lists method as described (Eden 
et al., 2009). KEGG pathway analysis was performed using the ClueGO plug-in of 
Cytoscape (Bindea et al., 2009).  
RNA Binding Protein Analysis 
To predict potential RNA-binding proteins that may be implicated in the observed 
changes in alternative splicing, alternatively spliced sequences were run through the 
RBPmap software (Paz et al., 2014) to detect potentially altered RNA binding proteins. 
The list of RNA binding proteins that were suggested by the software were then run 
through the Allen Brain Atlas (http://mouse.brain-map.org/) in order to ensure that they 
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were expressed in the murine hippocampus. All RNA binding proteins not expressed in 
the hippocampus were excluded.  
qPCR 
To measure mRNA expression, total RNA was extracted from freshly dissected 
hippocampal tissue, using the Aurum Total RNA for fatty and fibrous tissue kit (Bio-Rad) 
according to the manufacturer's instructions. cDNA synthesis and qPCR analysis were 
performed as previously described (Guzman et al., 2011). For alternative splicing 
experiments, the alternative exon levels were normalized to a constitutively expressed 
exon from the same gene. 
Primary Neuronal Cultures 
Primary mouse hippocampal neurons were produced from E16 embryos as 
previously described (Ostapchenko et al., 2013). Neurons were cultured for 15 days. 
Knockdown of hnRNPA2/B1 from the cultured neurons was achieved by treatment with 
a shRNA, as previously described (Berson et al., 2012). A separate set of cultured 
neurons was treated with 10µM of carbachol, 10µM of carbachol and 100µM Atropine, 
or 100µM Atropine alone for 48 hours. 
APP Processing 
Biochemical analysis of the processing of APP was performed as previously 
described (Dewachter et al., 2002). Forebrains from VAChT deficient and control mice 
were homogenized in 50mM Tris-HCl (pH 8.5), samples were then ultracentrifuge at 
135,000g for 1 hour at 4oC, and the supernatant was collected and analyzed by 
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Western blotting and ELISA. The pellet was re-suspended and ultracentrifuged again 
and diluted in 8M guanidine HCl to obtain the insoluble fraction for ELISA analysis.    
ELISA 
Murine β-amyloid was measured from the hippocampal homogenate using the 
Wako Human/Rat (Mouse) β-Amyloid (42) ELISA High-Sensitive Kit (Catalog Number: 
292-64501). The ELISA assay was performed according to the manufacturer's protocol. 
Congo Red Staining 
Congo red staining was performed as previously described (Thompson and 
Walker, 2015), using a Congo-Red solution (Sigma C-6277) in 100% ethanol.  
Silver staining 
Assessment of argyrophilic cells in the hippocampus was done by using 
NeuroSilverTM staining kit II (FD NeuroTechnologies, Inc., Baltimore, MD), which 
provides detection of degenerating neurons, including neuronal somata, axons, and 
terminals.  
Estimation of Hippocampal Volume 
NeuN immunohistochemistry was performed in order to estimate the volume of 
and number of neurons of hippocampal regions CA1, CA3, and the dentate gyrus (DG) 
as described (Beauquis et al., 2014). Briefly, tissue sections were stained with mouse 
monoclonal anti-NeuN (1:500 PhosphoSolutions, Catalog no. 583-FOX3), using the 
ABC kit (Vector Laboratories) and developed with 2 mM diaminobenzidine (Sigma, 
USA) and 0.5 mMH2O2 in 0.1 M Tris buffer. The total number of NeuN (T) cells in the 
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various hippocampal regions was estimated using the following formula:	 =
∗

	, where 
N is the cell density, V is the volume of the structure, and t is the thickness of the 
section. 
GSK3 Inhibition 
To inhibit GSK3 in VAChTNkx2.1-Cre-flox/flox mice, a cohort of aged animals (12 
months old, n=5 AR-A014418 treated, n=4 saline treated) were implanted with Alzet 
micro-osmotic pumps (Model 1004; DURECT Corp, Cupertino, Calif). The pumps were 
implanted subcutaneously in the intra-scapular region of each mouse. The reservoir of 
each pump was preloaded with 96 µL of either sterile saline solution or the GSK3 
inhibitor AR-A014418. The pumps administered 5 mg/kg/d of AR-A014418, a dose 
shown to produce a significant inhibition of GSK3 in vivo (Ly et al., 2013). During the 
implantation procedure, mice were anesthetized with ketamine (100 mg/kg) and 
xylazine (15 mg/kg). Drug treatment lasted for 28 days.  
Morris Water Maze 
The spatial version of the Morris water maze (MWM) was conducted as 
described previously to investigate spatial memory (Kolisnyk et al., 2013b; Martyn et al., 
2012; Vorhees and Williams, 2006). Briefly, animals were given four training trials a day 
(90 s each) for 4 d, with a 15 minute inter-trial interval. If the mice did not find the 
platform after 90 s during the learning phase, they were gently directed to the platform. 
On the fifth day, memory was assessed via a probe trial (60 s), during which the 
platform is removed and time spent in the target quadrant is measured. The task was 
performed in a 1.5-m-diameter pool with 25°C water. The platform was submerged 1 cm 
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 11 
below the surface of the water, and spatial cues (posters, streamers, and plastic props) 
were distributed around the pool. Sessions were recorded and analyzed using the ANY-
Maze Software. 
The classification of search strategies mice employed during training was defined 
as previously described (Garthe et al., 2009). An experimenter blind to genotypes 
scored search strategies as follows: (1) thigmotaxis, characterized by maintaining close 
proximity to the wall (>70% trial within 10-cm of wall); (2) random search, illustrated by 
global swimming with no classified strategy; (3) scanning, characterized by a preference 
for the central pool area (>50% trial within 35-cm of pool center); (4) chaining, 
characterized by searching near the correct radial distance of the platform to the wall 
(>75% trial 20–50-cm from the pool center, <15% within 10-cm of wall, and <10% within 
20-cm of pool center); (5) directed search, characterized by a preference for a 
passageway toward the platform or platform quadrant (>80% trial within a 50-cm-wide 
region from the start point to the platform); (6) focal search, characterized by a highly 
localized search near the platform (≥50% trial in a circular target zone with a 15-cm 
radius); (7) direct swim, characterized by a maintained heading toward the platform 
(Little to no deviation in path to reach platform from start point). Total block lengths were 
the sum of all blocks for one strategy and one mouse. 
Protein Isolation from Human post-mortem brain tissue. 
Samples from parietal cortical tissues from age/ sex-matched controls (n = 6, 3 
females and 3 males) and AD-affected individuals (n = 6, 3 females and 3 males) and 
information related to age and demographics have been previously published 
(Ostapchenko et al., 2013). The samples were homogenized in RIPA buffer 
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supplemented with protease inhibitor cocktail (Calbiochem), and Western blotting was 
performed as described above.  
Statistical analysis 
Sigmastat 3.5 software was used for statistical analysis. Student’s t-test was 
used for comparison between two experimental groups. Two-way ANOVA or two-way 
ANOVA with repeated measures (RM) were used when more than two groups were 
compared. 
Results 
Forebrain Cholinergic dysfunction modifies expression levels of hippocampal 
transcripts and alternative splicing 
To determine the contribution of cholinergic tone to the regulation of hippocampal 
transcript levels, we used VAChTNkx2.1-Cre-flox/flox mice, a mouse line with selective 
deletion of the VAChT gene from forebrain regions, including the medial septum, which 
contains cholinergic neurons that project to the hippocampus.  VAChT has been shown 
to be essential for ACh packaging and release (de Castro et al., 2009; Lima Rde et al., 
2010; Prado et al., 2006). Non-biased whole genome transcriptome RNA-sequencing of 
hippocampal samples from three VAChT-deficient and four control mice yielded a total 
of 14,200 expressed genes. Comparative analysis revealed that 1,098 genes were 
differentially expressed in VAChTNkx2.1-Cre-flox/flox hippocampi compared to control mice 
(Figure 1A-B, FDR corrected p < 0.05). Of those, 763 genes were upregulated and 362 
down-regulated in the transgenic mice. In addition, a linear regression analysis on 
reciprocal junction pairs detected roughly 4% of hippocampal transcripts in VAChTNkx2.1-
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Cre-flox/flox mice as alternatively spliced in high confidence as compared with control mice. 
Equal proportion of exon inclusion and exclusion events was observed; mainly events of 
cassette exons were detected (Figure 1C), suggesting widespread changes in several 
splicing regulation related pathways and/or cellular mechanisms (Soreq et al., 2014). 
We interrogated these differentially expressed/spliced genes for involvement in 
neuronal function and AD-like pathology. A number of genes involved in critical 
pathways including PI3K-Akt signalling pathway [a regulator of neuronal vulnerability 
(Endo et al., 2006; Gary and Mattson, 2001)], spliceosome regulation and regulation of 
microtubule-based processes were identified using Gene Ontology (GO) KEGG 
pathway analysis (Figure 1D, Table SI). qPCR validation and correlation between 
changes observed in RNA-Seq and in an independent mouse cohort are shown in 
Figure S1 for the different gene pathways and alternative splicing events. These results 
suggest that abnormal cholinergic signalling can effectively modulate several major 
gene pathways with potential to influence the function of target cells in the 
hippocampus. 
We also performed small molecule RNA-Seq and additional miRNA microarray 
hybridization experiments, and observed limited changes in miRNA expression in the 
hippocampus of VAChT-deficient mice (Figure S2). VAChTNkx2.1-Cre-flox/flox hippocampus 
showed a mature miRNA expression profile with only marginal differences from 
controls. Only 7 of 700 detectable miRNAs were differentially expressed, and of the 20 
miRNAs most highly expressed in the hippocampus, comprising 82% of total counts, 
none were differentially expressed (Figure S2). These findings point to alternative 
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splicing and transcription, or changes in mRNA turnover, rather than miRNA, as 
potential main contributors to phenotypes in VAChT-deficient mice. 
Cholinergic deficit triggers abnormal BACE1 alternative splicing and APP 
Processing  
One of the detected abnormally alternatively spliced genes in our database was 
the protease BACE1 (Figure 1D), which is responsible for the cleavage of APP (Luo et 
al., 2001). The predicted alternative splicing event in VAChT-deficient mice is expected 
to increase expression of BACE1-501, the active protein isoform (Mowrer and Wolfe, 
2008). qPCR analysis validated the predicted splicing event and demonstrated 
increased exon 3/4 inclusion for BACE1 (Figure 2A).  
Bioinformatics analysis using the RBP-Map tool revealed an enrichment of 
binding sites for hnRNPA2/B1 in BACE1 mRNA. hnRNPA2/B1 is part of a family of RNA 
binding proteins that regulate pre-mRNA splicing, trafficking and maturation (Bekenstein 
and Soreq, 2013). Notably, AD-associated impairments in cholinergic signalling are 
accompanied by decreased expression of hnRNPA2/B1 protein in the AD cerebral 
cortex and in cholinergic impaired mice (Berson et al., 2012; Kolisnyk et al., 2013a). 
Correspondingly, the hippocampus of VAChTNkx2.1-Cre-flox/flox mice showed reduced 
hnRNPA2/B1 protein levels (Figure 2B). We then investigated whether hnRNPA2/B1 
regulates BACE1 splicing by exposing primary hippocampal cultured neurons to 
lentivirus carrying shRNA against hnRNPA2B1. Our results showed changes in BACE1 
splicing similar to cholinergic deficiency (Figure 2C), directly implicating hnRNPA2/B1 in 
the regulation of BACE1 splicing. To test for the role of cholinergic signalling and the 
different cholinergic receptors in mediating this splicing event, we treated cultured 
Page 17 of 57 Cerebral Cortex
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 Cholinergic Control of Transcription and Pathology 
 15 
hippocampal neurons with the cholinergic mimetic carbachol. This treatment was able to 
decrease the proportion of BACE1-501. This decrease was blocked by co-treatment 
with the muscarinic antagonist atropine (Figure 2D). These data implicate muscarinic 
receptors in the regulation of BACE1 splicing. This splicing event in BACE1 predicts an 
increase in the levels of the mature BACE1 protein and indeed, immunoblot analysis 
revealed a 2-fold increase of BACE1 levels in the hippocampus of VAChT-deficient 
mice (Figure 2E).  
In late onset AD BACE1 expression is upregulated (Hebert et al., 2008) and it is 
thought to contribute to age-dependent progression in AD pathology (Ly et al., 2013). 
We therefore tested for changes in APP processing in VAChTNkx2.1-Cre-flox/flox mice. Aged 
VAChT-deficient mice (11-14 month old) displayed a modified pattern of Tris-soluble 
APP fragments (Figure 2F), similar to that of mouse models with APP/PS1 mutations 
(Jankowsky et al., 2004; Oddo et al., 2003). In contrast, membrane-bound C-terminal 
fragments of APP (α and β CTFs), alterations of which can suggest impaired proteolytic 
processing of the protein [Reviewed in (Selkoe, 2000)], were similar in VAChT-deficient 
mice and controls (Figure 2G). APP processing was not modified in aged Nkx2.1-Cre 
mice (Figure S3A), suggesting that this effect is due to cholinergic dysfunction rather 
than to Cre expression.  
We then assessed the levels of mouse amyloid peptides using an ELISA kit 
validated for both mouse and human Aβ peptides (Teich et al., 2013). The hippocampus 
of aged VAChTNkx2.1-Cre-flox/flox mice showed increased levels of soluble mouse Aβ 
peptide compared to controls (Figure 2H), reaching about one third of the levels of 
those found in aged 5XFAD mouse model of AD, which is one of the most aggressive 
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models of AD amyloidosis. In comparison, insoluble amyloid peptide was undetectable 
in the brains of VAChT-deficient mice, whereas it was highly abundant in the 5XFAD 
mice (Figure 2H). In addition, neither control nor VAChT-deficient mice displayed 
positive Congo red staining, unlike brain sections from 5XFAD mice, which exhibited 
numerous Congo red plaques (Figure 2I). These data indicate that although VAChT-
deficient mice show increased levels of soluble Aβ peptides, they do not seem to 
accumulate in extracellular amyloid plaques. Indeed, the murine amyloid peptide is 
much less prone to aggregation than human Aβ due to two amino acid changes 
(Jankowsky et al., 2007). 
Cholinergic deficit leads to age-dependent hippocampal tauopathy 
In AD, increased levels of soluble Aβ peptides are thought to precede abnormal 
phosphorylation of the microtubule associated protein tau (Iqbal et al., 2010). Previous 
reports suggested that cholinergic activity and tau phosphorylation might be inter-
related (Hellstrom-Lindahl, 2000). Therefore, we used immunofluorescence to assess 
levels of the AT180 tau epitope (T231/S235) in the hippocampus of VAChT-deficient 
mice. This phosphorylation-dependent antibody specific to pT231 has been shown to 
label approximately 70% of paired helical filaments (PHF) in AD brains (Goedert et al., 
1994). Phosphorylation at this epitope reduces the binding of tau to microtubules 
potentially increasing its toxicity (Lim et al., 2008). Immunofluorescence imaging 
revealed a robust increase of AT180 immunoreactivity in the hippocampus of 
VAChTNkx2.1-Cre-flox/flox mice compared to aged-matched controls (Figure 3A- 11-14 
month-old mice). To test if the positive immunoreactivity of pTau in VAChT-deficient 
mice is associated with an induction of pathological tau, immunofluorescence with MC1 
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antibody was performed. Positive reactivity of conformation-dependent MC1 antibody 
depends on the proximity of N terminal (aa 7-9) and C-terminal (313-333) amino acid 
sequences of tau, which is one of the earliest alterations of tau in AD (Weaver et al., 
2000; Wolozin et al., 1986). Immunostaining with MC1 revealed positive 
immunoreactivity in the hippocampus of aged cholinergic-deficient mice, but not in age-
matched controls (Figure 3B). 
In agreement with the immunofluorescence data, hippocampal extracts of 
VAChTNkx2.1-Cre-flox/flox mice showed approximately four-fold increases in pTau 
immunoreactive bands, including higher order oligomers detected with AT180, when 
compared to controls (Figure 3C and D). On the other hand, total tau and pTauS262 
levels were unmodified in VAChT-deficient mice (Figure 3C and D). Taken together, our 
data indicate that deletion of hippocampal VAChT induces hyper-phosphorylation of tau 
and leads to tau pathological conformation as detected by MC1, both of which are 
consistently observed in AD. These data suggest the potential for neuronal toxicity due 
to cholinergic dysfunction.  
Cholinergic deficiency exacerbates age-dependent neuronal vulnerability and 
impaired learning.  
Synaptic health is compromised in mouse models of AD and synaptic loss is a 
consistent finding in AD-affected individuals (Klein, 2006). To examine synaptic integrity 
we stained hippocampal sections with the synaptic marker PSD95. Aged VAChTNkx2.1-
Cre-flox/flox mice displayed hippocampal decreases in PSD95-immunoreactivity, increased 
microglial activation and up-regulation of inflammatory markers, in comparison to age-
matched controls, suggesting large-scale synaptic dysfunction in these mutants (Figure 
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4A-C). These observations predict neuronal vulnerability; therefore, we stained brain 
sections with silver, which accumulates in neurons that are more vulnerable to 
neurodegeneration (DeOlmos and Ingram, 1971). Aged VAChT-deficient mice 
presented intensified silver staining compared to controls; this increased silver staining 
was not observed in young VAChT-deficient mice (Figure 4D-E), suggesting that long-
lasting decrease in cholinergic signalling may increase the vulnerability of hippocampal 
neurons. Parallel staining of hippocampal sections from aged 5XFAD mice compared to 
control mice performed as a positive control revealed similar increases in silver staining 
as that for VAChT-deficient mice (Figure S4).  
Activated caspase-3, a marker of apoptosis, was augmented in young 
VAChTNkx2.1-Cre-flox/flox mice compared to controls (Figure 4F). However, aging 
significantly increased the number of activated caspase-positive cells in VAChT-
deficient mice when compared to controls (Figure 4F). Also, young VAChT-deficient 
mice showed no alteration in the number of NeuN positive cells across all regions of the 
hippocampus (Figure 4G, Figure S4); while NeuN positive cells in CA1 and CA3 region, 
but not dentate gyrus were decreased in aged VAChT-deficient mice (Figure 4G, Figure 
S4), predicting functional implications for this aging-related hippocampal neuronal 
vulnerability. Thus, impaired cholinergic signalling induces global changes in transcript 
levels, followed by age-related exacerbation of synaptic and neuronal vulnerability. 
To test whether long-lasting cholinergic failure may have age-dependent 
consequences in cognitive function, we subjected aged (11-14 months old) VAChT-
deficient mice to the MWM task. Young VAChT-deficient mice (3-6 months old) show 
little difference from controls in acquisition performance on the Morris Water Maze 
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(MWM) task (Al-Onaizi et al., 2016). In contrast, aged VAChT-deficient mice took 
significantly longer and swam a greater distance than age-matched controls to find the 
platform across the four days of acquisition (Figure S4E-F). Furthermore, aged VAChT-
deficient mice used distinct strategy preferences to find the platform, indicating that their 
deteriorated performance was due to modified learning capacities. Briefly, the analysis 
of search strategies used by each animal was based on a fixed set of criteria (Figure 
4H). At a young age, both controls and VAChTNkx2.1-Cre-flox/flox mice predominantly used a 
more direct strategy to reach the platform (strategies 5/6/7, Figure 4I). In contrast, aged 
VAChT-deficient mice used random swimming predominantly as their strategy to 
acquire the task (strategy 2, Figure 4I), while aged control mice maintained the use of 
more direct strategies. Aged VAChT-deficient mice also exhibited deficits in the probe 
trial (Figure S4G). Taken together, these results suggest that long-term cholinergic 
deficiency in VAChTNkx2.1-Cre-flox/flox mice led to progressive loss of neurons in the 
hippocampus that worsened spatial information acquisition and cognitive functioning. 
Cholinergic mediated age dependent pathology is partially mediated by GSK3 
activation 
In addition to APP processing and tau hyperphosphorylation, we observed other 
critical biochemical pathways altered in response to cholinergic deficiency, including 
aberrant GSK3 signalling, which has also been shown to play multiple roles in AD (Endo 
et al., 2006; Gary and Mattson, 2001). As several genes that regulate the PI3-AKT 
pathway were upregulated in VAChT-deficient mice (Fig. 1D, S1), we tested for 
dysregulation of PI3-AKT signalling pathway in these mice by evaluating the 
phosphorylation status of the AKT protein and its downstream target GSK3. AKT 
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presented decreased phosphorylation at residue Ser473, with unmodified Thr308 
phosphorylation, in VAChTNkx2.1-Cre-flox/flox hippocampus compared to controls (Figure 
5A). Additionally, GSK3α/β tyrosine phosphorylation, which reflects activation of GSK3, 
was increased in these mutants (Figure 5B). Hence in addition to increased levels of 
proteins involved in AD pathology, these results suggest potential contributions of GSK3 
activation in cholinergic-induced deficits.  
To test the role of GSK3 in the abnormal hippocampal changes in cholinergic-
deficient mice, we chronically treated a cohort of aged (11 months old) VAChTNKx2.1-Cre-
flox/flox mice with the GSK3 inhibitor AR-A014418 (Figure 5C).  After 28 days of 
treatment, we found that VAChT-deficient mice treated with AR-A014418 showed a 
significant decrease in GSK3 α and β tyrosine phosphorylation when compared to 
VAChTNKx2.1-Cre-flox/flox mice treated with saline (Figure 5D).  Increased phosphorylation at 
Tyr residues 216 or 279 augments GSK3 activity (Hur and Zhou, 2010) and examining 
GSK3 phosphorylation at these residues has been used to determine the effectiveness 
of AR-A014418 (Carter et al., 2014; Yadav et al., 2014). We then assessed some of the 
key alterations detected in the hippocampus of aged VAChTNKx2.1-Cre-flox/flox mice. AR-
A014418 treatment was able to significantly decrease tau T231 hyperphosphorylation 
and MC1-immunopositive tau in Western blots (Chai et al., 2011; Petry et al., 2014), by 
approximately 50% in VAChTNKx2.1-Cre-flox/flox mice when compared to saline VAChTNKx2.1-
Cre-flox/flox mice. Total levels of tau where unchanged (Figure 5E). Immunofluorescence 
staining (Figure 5F) also demonstrated reduced levels of T231 hyperphosphorylated tau 
in AR-A014418 treated mice. Compared to saline treated animals, AR-A014418 
treatment was able to significantly increase levels of PSD-95 protein (Figure 5G). 
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Interestingly, we observed no changes in protein levels of BACE1 following AR-
A014418 treatment in aged VAChTNKx2.1-Cre-flox/flox mice (Fig.S5A). Furthermore AR-
A014418 treatment did not alter the alternative splicing event in the BACE1 gene 
(Figure S5A). Together, these data suggest that the hnRNPA2/B1-mediated alternative 
splicing and subsequent increase in BACE1 protein level are not mediated by GSK3 
activation. Surprisingly, despite reduced levels of hyperphosphorylated tau, 1-month 
AR-A014418 treatment was unable to decrease the elevated levels of activated 
caspase-3, (Figure S5C-D).  
 Cholinergic dysfunction in human AD brains 
Whether cholinergic genes are expressed in lower levels in human AD brain 
compared to cognitively alert controls and may contribute to phenotypes detected 
herein is not fully understood. To examine that, we extracted total RNA from a cohort of 
24 adult human temporal gyrus samples collected at the Netherland Brain Bank (sample 
information in Table SII), including 8 sporadic AD patients and 16 from age-matched 
controls. We then profiled AD-related transcript differences by adopting the particularly 
deep SQUARETM RNA library construction approach (Hebenstreit and Teichmann, 
2011). Of those, 10,885 genes that were expressed showed a significant change. Next, 
we quantified the levels of those transcripts composing the expanded family of 
cholinergic regulator genes (Soreq, 2015). Detected cholinergic transcripts showed 
significantly lower expression levels than other protein-coding genes in the temporal 
gyrus of AD patients compared to aged-matched controls (Figure 6A).  
Brain samples from a distinct cohort of AD patients (Ostapchenko et al., 2013) 
supported the RNA-Seq analysis results by showing a significant VAChT loss in AD 
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brains compared to age and sex-matched controls (Figure 6B), in agreement with 
previous observations (Chen et al., 2011; Efange et al., 1997). Furthermore, the cohort 
of AD brains exhibited 50% decrease in hnRNPA2/B1 protein levels compared to 
age/gender-matched controls (Figure 6C), confirming previous results obtained with a 
distinct AD cohort (Berson et al., 2012). Additionally, we found a significant positive 
correlation between VAChT and hnRNPA2/B1 protein levels (Figure 6D). AD brain 
samples also showed drastic increases in tau-Thr231 phosphorylation (Figure 6E), 
which was inversely proportional to the levels of VAChT (Figure 6F). Our findings using 
cholinergic-deficient mice support an intricate timeline whereby cholinergic dysfunction 
per se precedes and may have strong influence in pathological changes observed in 
AD.  
Discussion 
We employed transcriptome and biochemical assays on cholinergic-deficient 
mouse brain samples to explore the impact of long-lasting forebrain cholinergic 
dysfunction. Whole-genome RNA sequencing demonstrated that cholinergic deficiency 
modifies expression levels and isoform abundance of several key transcripts related to 
Alzheimer’s disease in the hippocampus of VAChT-deficient mice. Cholinergic-mediated 
abnormal BACE1 mRNA splicing in VAChT-mutant mice increased BACE1 protein 
levels and APP processing. Accordingly, cholinergic deficiency caused a 10-fold 
increase in soluble mouse Aβ peptides, age-dependent hippocampal tauopathy, 
synaptic abnormalities, neuronal inflammation, neuronal vulnerability and cognitive 
decline. We also showed that GSK3 activation is critical for cholinergic modulation of 
tau hyperphosphorylation and synaptic vulnerability. Furthermore, we confirmed that 
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human AD brains present cholinergic dysfunction and showed that it correlates to 
changes in the levels of hnRNP A2/B1 and hyperphosphorylated tau. Our findings 
indicate that cholinergic impairments confer widespread hippocampal damage and 
malfunction. Furthermore, our data support a causal role for cholinergic signalling as a 
surveillance mechanism controlling hippocampal transcript levels, maintenance of 
cognitive function and neuronal viability in mice.  
Our RNA sequencing analysis revealed a group of differentially expressed 
transcripts related to spliceosome regulation in the hippocampus of VAChTNkx2.1-Cre-flox/flox 
mice, suggesting that the splicing machinery in these mutants could be altered. In fact, 
a significant number of alternative splicing event abnormalities were observed in the 
hippocampus of VAChT-deficient mice. These results are consistent with previously 
reported global changes of alternative splicing in the AD brain (Bai et al., 2013; Berson 
et al., 2012; Tollervey et al., 2011). Importantly, spliceosome signalling pathway 
changes can have broad implications for gene regulation [reviewed in (Shin and 
Manley, 2004)]. 
Alternative splicing in the nervous system is particularly widespread and is 
essential for multiple aspects of neuronal function (Raj and Blencowe, 2015). However, 
the signal-transduction pathways that regulate splicing are not well known (Shin and 
Manley, 2004). Our study adds a role for cholinergic signalling in the maintenance of 
balanced alternative splicing. At least part of the cholinergic-control of alternative 
splicing seems to involve hnRNPA2/B1. We have shown that cholinergic deficiency in 
the cortex (Berson et al., 2012; Kolisnyk et al., 2013a) and hippocampus (Figure 2B) 
leads to decreased expression of the hnRNPA2/B1 protein. Related work demonstrated 
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that hnRNPA2/B1 is a cholinergic regulated splicing factor (Kolisnyk et al submitted). 
Importantly, knockdown of hnRNPA2/B1 in cultured hippocampal neurons shifted 
splicing of BACE1 mRNA towards increased expression of mRNA species coding for 
the BACE1-501 protein isoform as observed in the hippocampus of VAChT-deficient 
mice. This splicing change led to increased expression of the BACE1 protein that was 
accompanied by a pattern of APP processing similar to that observed in commonly used 
mouse models of AD. The alternative splicing event in BACE1 observed in VAChT-
mutant mice is regulated my M1 muscarinic receptors (Kolisnyk et al., submitted). 
Cholinergic tone has been thought to regulate APP processing through 
muscarinic receptors (Davis et al., 2010; Nitsch et al., 1992). Specifically, M1 signalling 
has been shown to regulate the stability of the BACE1 protein (Davis et al., 2010). 
BACE1-501 is a more stable and active form of the protein (Mowrer and Wolfe, 2008). 
Remarkably, BACE1 expression is increased in late-onset AD (Hebert et al., 2008). Our 
data suggest potential mechanisms by which cholinergic regulation can affect BACE1 
expression and AD pathology. Interestingly, our data suggest changes in alternative 
splicing occurs post-transcriptionally and independent of GSK3 signalling. Thus, 
cholinergic deficiency may affect BACE1 expression differently than previously 
described in AD, in which GSK3 can regulate BACE1 transcription by increasing 
promoter activity (Ly et al., 2013). Our findings promote upstream cholinergic 
mechanisms as a target for diminishing aberrant APP processing in AD.  
In addition to increased levels of soluble Aβ, VAChTNkx2.1-Cre-flox/flox mice also show 
tau hyper-phosphorylation, which destabilizes microtubules and significantly disrupts 
axonal transport. Tau hyper-phosphorylation may also contribute to increased 
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vulnerability leading to neuronal death (Billingsley and Kincaid, 1997). In fact, VAChT-
deficient mice show age-dependent increases in hippocampal argyrophilic staining and 
neuronal death.  
Oligomeric protein aggregation has been linked to toxicity and to 
neurodegenerative disorders, including AD (Maeda et al., 2006). The formation of NFTs 
alone is insufficient for neurodegeneration, yet oligomeric tau may contribute to 
neurodegeneration and synaptic loss in AD (Berger et al., 2007; de Calignon et al., 
2012). These observed changes in tau in VAChT-deficient mice (i.e. increased oligomer 
formation), the associated age-dependent increase in immunoreactivity of activated 
caspase-3, and ultimately neuronal loss all support a relationship between cholinergic 
failure and AD-like pathology in mice.  
Tau hyper-phosphorylation can occur due to the increased activity of GSK3, 
which subsequently leads to an array of impairments, including disruption of LTP 
(Hooper et al., 2007) and cell death in vitro (Zheng et al., 2002). GSK3 over-activation is 
an important hallmark in AD (Hooper et al., 2008). Thus, the GSK3 overactivation 
observed in VAChT-mutant mice represents a potential mechanism by which reduced 
cholinergic activity may have multiple influences in AD pathology in target cells. We 
tested this hypothesis by pharmacological inhibition of GSK3 in aged VAChT-deficient 
mice. GSK3 inhibition was able to decrease tau hyperphosphorylation. Also, GSK3 
inhibition partially restored PSD95 protein levels, but did not decrease caspase-3 
activation. These findings demonstrate that cholinergic-induced changes in tau and in 
amyloid processing are potentially independent of each other and suggest that 
cholinergic dysfunction is contributing to the pathological outcomes in these animals by 
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altering multiple pathways. The pharmacological inhibition of GSK3 was tested in mice 
in which certain pathology was already present (11-12 month-old mice). Hence, further 
experiments should test longer treatments with the compound or genetic ablation of 
GSK3 genes in VAChT-deficient mice to comprehensively dissect the contribution of 
overactive GSK3 in other phenotypes.  
Aged VAChT-deficient mice showed a decrease in the number of hippocampal 
neurons, a deficiency that was not observed in young mutants, suggesting that 
cholinergic tone may play a role in guarding hippocampal neuronal health. Additionally, 
aged VAChT-deficient mice showed increased neuroinflammation and reduced number 
of synapses; which are pathologies observed in AD brains (DeKosky and Scheff, 1990; 
Rogers and Shen, 2000; Smale et al., 1995). Mice with excess acetylcholinesterase, 
which present decreased cholinergic function, also show neuroinflammation (Shaked et 
al., 2009). Furthermore, similar to our observation, mice lacking the β2 nicotinic receptor 
subunit show age-dependent loss of hippocampal neurons (Zoli et al., 1999). Of note, 
hippocampal neuronal loss is a critical feature in AD, which is not observed in mouse 
models overexpressing APP and or presenilin 1 with human AD mutations (Stein and 
Johnson, 2002). Hence, long-term cholinergic deficiency may model this aspect of AD in 
a better way. Potential mechanisms involved in cholinergic dysfunction induced 
pathology are shown on Figure 7.  
In line with an age-dependent loss of hippocampal neurons, we found that aged 
VAChT-deficient mice showed significant impairments in their learning strategy in the 
MWM task. Poor performance and acquisition on the MWM task has been associated 
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with loss of neurons in the hippocampus (Olsen et al., 1994). This suggests that 
neuronal loss in the hippocampus has functional consequences in mice as well.  
In AD brains, we found evidence of cholinergic decline and showed a striking 
relationship between VAChT levels and tau hyper-phosphorylation. Together with the 
mouse data, these observations support the notion that deficient cholinergic signalling in 
AD may correlate to key pathological events, including Tau hyper-phosphorylation.  
Our data reveal that cholinergic deficiency can affect a number of transcriptional 
processes, disturb splicing of key genes and interfere with protein networks that 
normally protect neurons. Interestingly, recent work revealed that basal forebrain 
cholinergic neurons present intraneuronal Aβ accumulation even in young adults, which 
may contribute to their selective vulnerability in AD (Baker-Nigh et al., 2015). 
Cholinergic neurons are thought to be highly dependent on the presence of trophic 
factors for their optimal function and survival (Boskovic et al., 2014; Naumann et al., 
2002), which may also contribute to their demise. Regardless of the mechanisms for 
increased cholinergic vulnerability in AD, it seems that cholinergic dysfunction persisting 
for a long period is highly related to hippocampal pathology and amyloid accumulation 
(Teipel et al., 2014).  
In short, our results suggest that long-term cholinergic failure per se, which we 
model by disrupting synaptic cholinergic function, can trigger AD-like pathology in mice. 
More importantly, we find that long-term cholinergic deficiency leads to age-dependent 
cognitive decline that is related to neuronal death, a key feature of late-onset AD that is 
not modeled in mice overexpressing human genes with AD-related mutations. Our 
experiments provide a mechanism to explain how decreased cholinergic tone, for 
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example due to long-term use of anti-cholinergic drugs, could lead to increased risk of 
dementia (Gray et al., 2015), which may depend on global changes of RNA metabolism, 
including alternative splicing and gene expression. It remains to be determined if 
rescuing cholinergic function prior to development of AD could have an impact in the 
risk of dementia or AD-related pathology. However, it is noteworthy that recent 
observations in potential prodromal AD-affected individuals indicate that cholinesterase 
inhibition decreases the rate of hippocampal atrophy by 45% during one-year treatment 
(Dubois et al., 2015). Our data points towards cholinergic signalling being a global 
mediator of several distinct processes that when dysfunctional lead to pathology. 
Developing effective strategies to reverse the cholinergic deficits in the AD brain may 
therefore prove to be more fruitful then specific therapies based on reversing the 
individual processes it regulates.   
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Figure 1. Forebrain deletion of VAChT induces alterations in hippocampal transcriptome. (A) Principal 
component analysis of transcripts from the hippocampi of control (VAChTflox/flox; gray circles) and 
VAChTNKx2.1-Cre-flox/flox (red circles) mice. (B) Cluster analysis of differentially regulated transcripts in 
the hippocampus of VAChTNKx2.1-Cre-flox/flox (n=3) mice compared to controls (n=4). (C) Number of 
genes at indicated significance cut-off that were found to have an exon inclusion or exclusion event and 
summary of alternative splicing events. (D) List of genes from the PI3K-AKT pathway (grey shading), 
Spliceosome pathway (blue shading), Microtubule polymerization pathway (green shading) and other AD 
genes of interest (yellow shading), identified from KEGG pathway analysis of altered transcripts in 
VAChTNKx2.1-Cre-flox/flox mice. For each gene corresponding fold change, corrected statistical significance 
levels, and RNA expression change is also shown. Altered mRNA expression of these genes has been 
confirmed by qPCR (see Fig. S1).  
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Figure 2. Disrupted APP processing and alternative splicing of BACE1 in cholinergic deficient mice. (A) qPCR 
analysis of alternative splicing events for BACE1 in the hippocampus of controls and (VAChTflox/flox; gray 
bars) and VAChTNKx2.1-Cre-flox/flox (red bars). Alternative exon levels are normalized to a constitutive 
exon from the same gene (n=6, data are mean ± SEM. **P<0.01). (B) Representative Western blot and 
quantification of hnRNPA2/B1 protein expression in the hippocampus of controls (VAChTflox/flox; gray bars) 
and VAChTNKx2.1-Cre-flox/flox (red bars) mice. hnRNPA2/B1 expression was normalized to actin (n=4, data 
are mean ± SEM. **P<0.01). (C) Quantification of the BACE1 alternative splicing in primary neuron cultures 
treated with hnRNPA2B1-shRNA (*P<0.05). (D) Quantification of the BACE1 alternative splicing in primary 
neuron cultures treated with 10mM Carbachol and Atropine (n=4, data are mean ± SEM. **P<0.05). (E) 
Representative Western blot and quantification of BACE1 protein levels in the hippocampus of controls 
(VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars) mice. BACE1 expression was 
normalized to actin (n=3, data are mean ± SEM. *P<0.05). (F) Biochemical analysis and quantification of 
murine APP fragments in brain homogenates of aged expressed as a % [(Signal intensity of the 
fragment/signal intensity of full-length protein) x100]. 11-14 month old controls (VAChTflox/flox; gray 
bars), VAChTNKx2.1-Cre-flox/flox (red bars) and APPswe/PS1dE9 (green bars) hippocampal tissue extracts 
were resolved by Western blotting (data are mean ± SEM n=3). (G) Analysis of membrane-bound APP 
fragments in aged controls (VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars) and 
APPswe/PS1dE9 (green bars) (data are mean ± SEM n=3). (H) Murine soluble and insoluble levels of Aβ42 
in aged (11-14 months old) controls (VAChTflox/flox; gray bars), VAChTNKx2.1-Cre-flox/flox (red bars) and 
5xFAD (black bars) measured by ELISA (n=4) (I) Congo red staining in the CA1 region of the hippocampus 
in aged (11-14 months old) controls, VAChTNKx2.1-Cre-flox/flox, and 5xFAD mice. Arrowheads indicate 
positive-Congo red staining suggestive of amyloid plaques. (n=3, Scale bar, 100µm).  
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Figure 3. Hippocampal cholinergic failure triggers tauopathy in an age-dependent manner. (A) 
Phosphorylated Tau levels monitored by immunolabeling with phosphorylation-dependent antibodies specific 
to pT231. Representative images of pT231 and Hoeschst labeling in the hippocampus of aged (11-14 month 
old) controls (left) and VAChTNKx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (B) 
Representative images of MC1 and Hoeschst labeling in the CA1 region of the hippocampus of controls (left) 
and VAChTNKx2.1-Cre-flox/flox (right) mice. (n=3, Scale bar, 100µm). (C) Western blot analysis of controls 
(VAChTflox/flox) and VAChTNKx2.1-Cre-flox/flox aged (11-14 month old) hippocampal samples for tau using 
phosphorylation-dependent anti-tau antibodies pT231, Ser 262 and for total Tau protein expression. (D) 
Quantification of Western blots. pT231, Ser 262, and total tau expression were normalized to actin (n= 4, 
data are mean ± SEM. **P<0.01).  
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Figure 4. Hippocampal cholinergic failure leads to increased neuronal vulnerability and worsens cognitive 
functioning. (A) Immunofluorescence imaging showing PSD-95 protein levels in the hippocampus of aged 
controls or VAChTNkx2.1-Cre-flox/flox mice and corresponding (B) Western blot analysis for PSD-95 protein 
levels in the hippocampus of VAChTNkx2.1-Cre-flox/flox mice compared to controls (t(6)=4.286, p=0.0052, 
n=4). (C) Immunofluorescence imaging and quantification showing CD-68 immunoreactivity in the 
hippocampus of aged VAChTNkx2.1-Cre-flox/flox mice as well as levels of IL-1 transcripts as measured by 
qRT-PCR (t(10)=2.312, p=0.0434, n=6) and IL-6 transcripts as measured by qRT-PCR (t(10)=2.882, 
p=0.0204) (Data are mean +/- S.E.M., *P<0.05, n=6). (D) Representative images of silver staining in the 
CA1 region of young (3-6 months) and aged (11-14 months) mice. Scale bar, 100µm. (E) Quantification of 
silver stain-positive cells between young and aged hippocampi of controls (VAChTflox/flox; gray bars) and 
VAChTNKx2.1-Cre-flox/flox (red bars). (n=5, data are mean ± SEM. **P<0.01). (F) Representative 
immunofluorescence images for activated-caspase 3 labelling in the hippocampi of young (Top) and aged 
(Bottom) mice. Quantification of activated caspase-3 immunolabelling in young and aged hippocampi of 
controls (VAChTflox/flox; gray bars) and VAChTNKx2.1-Cre-flox/flox (red bars). (n= 3, data are mean ± 
SEM. *P<0.05, **P<0.01, Scale bar, 100µm). (G) Distribution of neuron-specific nuclear antigen (NeuN)-
positive neurons in the CA1 region of the hippocampus in young (top) and aged (bottom) mice (Scale bar, 
100µm). Quantitative comparison of the number of neurons labelled by NeuN in the CA1 region of the 
hippocampus in young (top) and aged (bottom) mice (n= 6, data are mean ± SEM. *P<0.05). (H) 
Representative examples of the 7 classified criteria to score the strategies mice used to perform in the 
MWM. Strategies are color coded. (I) Strategy plot reflecting the mean strategy-recruitment values for the 
first and fourth trials of each day for young (left) and aged (right) mice. Quantification comparison of total 
block length values of individual mice and their employed strategies over the course of 4-day training 
period. Grey bars represent control mice and red bars represent VAChT-deficient mice. (n= 8, data are 
mean ± SEM. *P<0.05 **P<0.01).  
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Figure 5. Cholinergic mediated tau hyperphosphorylation is regulated by GSK3 activation. (A) 
Representative Western-blot and quantification analysis of pAKT(S473) and pAKT(Thr308) levels in the 
hippocampus of VAChTNkx2.1-Cre-flox/flox mice. (n=4, data are mean ± SEM. *P<0.05 (B) Representative 
Western blot and quantification analysis of phospho-GSK3α and β in the hippocampus of aged (11-14 month 
old) controls (left) and VAChTNKx2.1-Cre-flox/flox (right) mice. Levels of pGSK3α and β to the respective 
GSK3 (n= 5 and 3, data are mean ± SEM. **P<0.01, ***P<0.001). (C) Implantation of osmotic pumps and 
delivery of AR-A014418 to aged VAChTNKx2.1-Cre-flox/flox mice. (D) Representative Western blot and 
quantification analysis of phospho-GSK3α and β in the hippocampus of aged VAChTNKx2.1-Cre-flox/flox 
mice treated with AR-A014418 or saline. (E) Western blot analysis aged VAChTNKx2.1-Cre-flox/flox treated 
with AR-A014418 or saline for Tau hyper-phosphorylation at T231, MCI immunopositive tau and total Tau 
protein expression. (F) Representative immunolabelling of reduced T231 Tau in the hippocampus of aged 
VAChTNKx2.1-Cre-flox/flox mice (Scale bar, 100µm). (G) Western blot analysis for PSD-95 protein levels in 
the hippocampus of VAChTNkx2.1-Cre-flox/flox mice treated with AR-A014418 or saline. (n= 4 saline 
treated, n=5 AR-A014418 treated, data are mean ± SEM. *P<0.05 ***P<0.001).  
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Figure 6. Cholinergic Failure in the human AD Brain associates with loss of hnRNPA2/B1 and 
hyperphosporylation of tau. (A) Cholinergic Genes are down-regulated in the AD temporal gyrus. Shown are 
cumulative distribution functions (CDFs) for the global change in the expanded family of cholinergic genes 
(as listed in Soreq, 2015) compared to global expression patterns between AD and control brain tissues (n= 
8, Kolmogorov Smirnov p=0.03, red and blue lines, correspondingly). (B) Western blot analysis of VAChT 
protein levels in AD brains. (C) Western blot analysis of hnRNPA2/B1 protein levels in AD brains. (D) 
Correlation between hnRNPA2/B1 protein levels and VAChT protein levels in AD brains. (E) Western blot 
analysis of Tau-Thr231 phosphorylation levels and (F) correlation between VAChT protein levels and Tau 
Thr-231 phosphorylation levels. (n= 6, data are mean ± SEM. *P<0.05 **P<0.01).  
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Figure 7. Summary of our findings. (A) In control animals, cholinergic input from the medial septum 
regulates target neurons in the hippocampus, through nicotinic and muscarinic acetylcholine receptors. 
Long-term cholinergic signaling maintains transcriptome integrity likely by a combination of muscarinic and 
nicotinic activation. These maintain balance of signaling pathways that regulate AD-like pathology. (B) 
Conversely, in cholinergic deficient mice, which models long-term cholinergic dysfunction, lack of signaling 
by muscarinic and nicotinic receptors affects differential expression of spliceosome-related genes and 
reductions in hnRNPA2/B1. BACE1 mRNA is abnormally spliced leading to an increase of BACE1 expression. 
As a consequence, APP processing is altered, yielding accumulation of soluble Aβ peptides. Furthermore, 
abnormal gene expression influences AKT-GSK3 modulatory genes with consequences for AKT and GSK3 
phosphorylation. These changes contribute to increases in pathological tau phosphorylation and misfolding, 
neuroinflammation, synaptic loss, hippocampal neuronal death and ultimately leading to cognitive decline in 
these animals.  
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Supplementary Table 2: Data for cohort of human brain samples, collected from the Netherland Brain 
Bank, from which total RNA was extracted and sequenced, n=24. 
NBB id sex age Post 
mortem 
delay 
ph weight region 
2008-047 M 77 06:35 6.10 1250 superior temporalis gyrus 
2000-066 M 80 04:20 7.08 1160 inferior temporalis gyrus 
2007-025 M 82 05:15 6.34 1182 superior temporalis gyrus 
2007-052 M 82 04:15 6.41 1205 medial temporalis gyrus 
2009-040 M 83 06:10 5.91 1102 superior temporalis gyrus 
2008-029 M 84 08:05 5.95 1195 superior temporalis gyrus 
2001-044 M 85 04:25 6.20 1383 superior temporalis gyrus 
2001-063 M 85 04:45 6.38 1215 superior temporalis gyrus 
2010-016 M 86 06:15 ? 1211 superior temporalis gyrus 
2009-107 M 88 04:40 6.22 1054 superior temporalis gyrus 
2005-010 M 93 04:30 6.46 1040 superior temporalis gyrus 
2002-087 M 71 07:40 6.20 1150 superior temporalis gyrus 
2001-016 M 77 08:25 7.19 1118 superior temporalis gyrus 
2000-015 M 78 05:35 6.63 1417 inferior temporalis gyrus 
2005-044 M 80 07:15 5.80 1331 superior temporalis gyrus 
2001-021 M 82 07:40 6.07 1318 inferior temporalis gyrus 
2009-005 M 82 05:10 6.75 1087 superior temporalis gyrus 
2001-086 M 88 07:00 6.84 1368 superior temporalis gyrus 
2003-035 M 96 06:30 6.65 1300 superior temporalis gyrus 
2005-019 M 74 05:00 6.70 1115 superior temporalis gyrus 
2003-084 M 82 10:00 6.53 1488 superior temporalis gyrus 
2009-039 M 82 12:55 6.21 1406 superior temporalis gyrus 
2005-073 M 87 06:05 6.96 1468 superior temporalis gyrus 
2009-075 M 88 07:00 6.76 1230 superior temporalis gyrus 
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Supplementary Table 3: Number of detected genes (RPKM>1) per patient, per SQUARE field. Rows are 
patients and columns are SQUARE fields.  
  1 2 3 4 5 6 7 8 9 10 11 12 
AD 1 6152 6729 6154 7224 9942 6284 4273 5176 6504 7879 5815 7500 
2 6961 6995 6251 7516 9611 6478 4549 5294 6698 7778 6204 7747 
3 6945 7107 6627 7388 9746 6221 4529 5037 6789 7983 6145 6059 
4 6811 6704 6530 7555 9664 6193 2877 4868 6250 7976 6246 8079 
5 6123 6417 5848 7628 9529 5953 4637 4639 6140 7481 5814 7654 
6 6956 7093 6308 7469 9927 6730 4542 4951 6091 7465 5699 6550 
7 6310 6217 5749 7176 9410 5910 4393 4695 6247 7203 5531 7122 
8 6770 6999 6436 7352 9675 6730 4451 5233 6761 7500 6114 7589 
Con 9 6374 6456 5957 6785 9250 6039 3889 4726 6506 7182 5307 6633 
10 6820 6919 6083 6883 9270 5950 4367 4861 6763 7729 5266 6545 
11 5771 6029 5191 6705 9445 5654 4197 4565 6188 6804 5649 6986 
12 5660 7181 6486 7208 10160 7867 5148 5422 6939 8082 6243 6555 
13 6332 6962 6220 6468 9430 6576 3876 5126 6959 7805 5361 6657 
14 6103 6486 5507 7139 9583 5781 4467 4604 6150 7328 5632 7412 
15 6380 6414 5592 6486 9377 5557 3940 4277 6225 7869 5571 7090 
16 6511 6673 6217 7495 9710 6147 4238 4947 6788 8011 5732 7296 
 17 6265 6450 5903 7247 9142 5907 4403 4718 6022 7212 5424 7478 
18 7153 7552 6945 7596 9822 6549 4382 5424 7282 8388 5926 7285 
19 6294 5943 5668 7300 9259 5648 4255 4416 6108 7468 5690 7321 
20 6268 6583 5753 7391 9732 6125 4635 4815 5896 7847 5733 7395 
21 7674 7822 6969 8201 10588 7826 5027 5787 7348 8095 6059 7434 
22 7274 7185 6793 7824 9945 6982 4755 5377 7258 8310 6185 7737 
23 7149 7073 6654 7206 9895 6774 4890 5274 6915 8485 5796 8190 
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24 5676 6113 5303 6938 9863 6393 4630 4835 6651 7721 5964 6474 
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